Abstract: TH-PO0923
Incidence of Cytomegalovirus Infection or Disease Using Valganciclovir Prophylaxis or Preemptive Therapy in Living-Donor Kidney Transplant Recipients at Intermediate Risk for CMV on a Basiliximab-Based Regimen
Session Information
- Transplantation: Clinical - Glomerular Diseases, Infections, and Rejection
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2102 Transplantation: Clinical
Authors
- Palacios, Alicia Daniela, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Andrade-Sierra, Jorge, Universidad de Guadalajara, Guadalajara, Jal., Mexico
- Monroy, Celeste Araceli, Universidad de Guadalajara, Guadalajara, Jal., Mexico
- Evangelista-Carrillo, Luis Alberto, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
- Cerrillos, Jose Ignacio, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jal., Mexico
Background
The most frequent viral complication following a kidney transplant is cytomegalovirus (CMV) infection, which can have long-term effects on graft function and survival. Our objective was to assess the incidence of CMV infection and illness in kidney transplant patients who were at intermediate risk for CMV utilizing valganciclovir prophylaxis or preemptive therapy, and to evaluate the effect this had on allograft function.
Methods
A randomized, open-label clinical trial, from March 2024 to March 2025, with a final sample of 67 patients. All patients with a PCR test during the first 6 months were enrolled in the preliminary analysis. Prophylactic therapy with valganciclovir (450 mg every 12 hours) was administered for 3 months; the preemptive group underwent quantitative CMV PCR every week for 3 months.
Results
The demographic results are described in the table.
At 6 months of follow-up, we did not find significant differences in the incidence of cytomegalovirus. Only one patient in the preemptive group had documented viremia results with PCR.
Conclusion
In patients at intermediate risk for CMV under an induction immunosuppression regimen with Basiliximab, preemptive therapy is no different from the use of valganciclovir in the prevention of CMV.
| Prophylactic therapy N=22 | Preemptive group N=16 | |
| Age (years) | 36±11 | 34±7 |
| Male-gender n (%) | 10 (45.5) | 8 (50) |
| Body Mass Index | 24.4± 4 | 23.6±4 |
| Warm Ischemia Cold Ischemia | 2.3 ± 1.4 52.56 ± 26 | 2.5 ±1.9 58.06 ± 30 |
| Parameters at 1 month Leukocytes x 109/L Lymphocytes x 109/L Hemoglobin (%) Platelets x 109/L Creatinine (mg/dL) GFR (ml/min) Tacrolimus levels ng/mL | . 11.135 ± 4.4 1.9 ± 1.02 11.16 ± 1.8 292.95 ± 102.8 1.15 ± 0.45 71.22 ± 20.70 11.53 ± 9.8 | . 11.62 ± 5.8 1.5 ±1.1 11.81 ± 1.7 323.12 ± 147.23 1.2 ± .34 64.98 ± 18.92 12.6 ± 6.3 |
| Parameters at 6 months Leukocytes x 109/L Lymphocytes x 109/L Hemoglobin (%) Platelets x 109/L Creatinine (mg/dL) GFR (ml/min) Tacrolimus levels (ng/mL) | . 11.9 ± 3.6 2.1 ± 0.4 12.08 ± 1.12 385 ± 102 1.6 ± 0.61 48 ± 17.5 10.01 | . 3.61± 1.5 1.70± 1.0 13.8 195 ± 78 1.4 56.7 12.3 |